According to Zacks, “CHF Solutions, Inc. is a medical device company which focused on commercializing the Aquadex FlexFlow (R) System. Its commercial product Aquadex system, is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. CHF Solutions Inc., formerly known as Sunshine Heart Inc., is headquartered in Minneapolis. “
Separately, ValuEngine upgraded CHF Solutions from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.
CHF Solutions (NASDAQ:CHFS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($1.93) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.46) by ($0.47). The firm had revenue of $1.68 million for the quarter. CHF Solutions had a negative return on equity of 193.21% and a negative net margin of 306.81%. Equities research analysts anticipate that CHF Solutions will post -6.02 earnings per share for the current fiscal year.
A hedge fund recently bought a new stake in CHF Solutions stock. Anson Funds Management LP acquired a new position in shares of CHF Solutions Inc (NASDAQ:CHFS) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 95,508 shares of the company’s stock, valued at approximately $278,000. Anson Funds Management LP owned about 3.69% of CHF Solutions at the end of the most recent reporting period. Institutional investors and hedge funds own 14.82% of the company’s stock.
About CHF Solutions
CHF Solutions, Inc, a medical device company, focuses on the provision of solutions for patients suffering from fluid overload. The company's commercial product is the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.
Further Reading: How analysts view the yield curve
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CHF Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CHF Solutions and related companies with MarketBeat.com's FREE daily email newsletter.